Abbott Launches Updated Oncodetect Blood Test

The advanced diagnostic tool screens for 5,000 genetic markers to help identify potential cancer recurrence after treatment.

Updated on Oct. 31, 2026 in Cancer

Abbott Launches Updated Oncodetect Blood Test

Live Poll

Is now a good time for patients to prioritize advanced molecular cancer screening in their healthcare?

Abbott has officially released an upgraded version of its Oncodetect blood test designed to detect molecular signs of cancer following treatment. This version monitors 5,000 genetic markers, a significant increase over the 200 changes identified by the original test.

Why it matters

The testing assists clinicians in determining if cancer remains in the body after initial treatment, potentially guiding follow-up care for millions of patients. It marks a shift toward more comprehensive molecular screening for solid tumors.

The updated test identifies up to 5,000 genetic markers compared to 200 in its predecessor. Clinical results showed a 90% detection rate for triple-negative breast cancer recurrence within five years, while 14 esophageal cancer patients showed molecular signs before clinical recurrence.

The players

Abbott

This global medical device and health care company specializes in diagnostics, medical devices, nutritionals, and branded generic medicines.

The details

The technology works by analyzing a patient's initial tumor sample to map unique DNA markers, which are then tracked through periodic blood tests to identify recurring molecular signals. Abbott acquired the developer of this diagnostic technology for $23 billion in March.

Abbott acquired the developer of the test in March 2026.
The SimpleScreen blood test launched in September 2026.
Abbott launched the updated Oncodetect test on October 26, 2026.

Health Landscape

This product launch follows the preliminary findings reported in over 20 active clinical studies currently evaluating the efficacy of the diagnostic test. The expansion of this technology reflects a broader push to improve post-treatment monitoring for solid tumors.

Patients with solid tumors may soon have access to more precise monitoring to detect potential cancer recurrence earlier. Consult with an oncologist to determine if molecular blood testing is a suitable component of your post-treatment care plan.

The takeaway

Advanced blood testing is changing how clinicians monitor cancer survivors for signs of disease recurrence. Patients should discuss the potential utility of these new diagnostic markers with their healthcare providers.